Table 3.
Classifcation | Compounds | Cancer types | Mechanisms of pyroptosis induction | References |
---|---|---|---|---|
Chemotherapy drugs | Decitabine/Azacitidine | MDS/AML | Caspase3/GSDME | (117) |
Topotecan/Etoposide/Cisplatin | neuroblastoma | Caspase3/GSDME | (117) | |
Cisplatin/PTX | Lung cancer | Caspase-3/GSDME | (165) | |
Lobaplatin | CRC | ROS/JNK/Caspase-3/GSDME | (166) | |
DOX | breast cancer | ROS/JNK/Caspase-3/GSDME | (159) | |
Natural products | Dioscin | OS | Caspase-3/GSDME | (169) |
DHA | ESCC | PKM2-Caspase-8/3-GSDME | (170) | |
CME | Lung cancer | Caspase-3/GSDME | (170, 171) | |
CBD | HCC | Caspase-3/GSDME | (25) | |
Tanshinone IIA | Cervical cancer | miR-145/Caspase-1/GSDMD | (168) | |
Berberine | HCC | Caspase-1 | (172) | |
Reagents | C10 | Prostate cancer | PKCδ/JNK/Caspase-3/GSDME | (173) |
BI 2536 | OC | Caspase-3/GSDME | (28) | |
α-NETA | OC | Caspase-4/GSDMD | (167) | |
13d | Lung Cancer | inhibit NF-kB pathway | (174) |
PTX, paclitaxel; DOX, doxorubicin; DHA, Dihydroartemisinin; CME, Cordyceps militaris extract. CBD, Cannabidiol; C10, 3’,5’-diprenylated chalcone; α-NETA, 2-(α-naphthoyl) ethyltrimethylammonium iodide; 13d, low toxicity NF-kB inhibitor; MDS, myelodysplastic syndromes; AML, acute myeloid leukemia; CRC, colorectal cancer; OS, osteosarcoma; ESCC,esophageal squamous cell carcinoma; HCC, hepatocellular carcinoma; OC, ovarian cancer; GSDME, gasdermin E; GSDMD, gasdermin D; ROS, reactive oxygen species; JNK, c-Jun N-terminal kinase; PKM2, pyruvate kinase isoform M2; miR-145, microRNA-145; PKCδ, protein kinase C delta; NF-kB, Nuclear factor kB.